ANDROGRAPHOLIDE DERIVATIVES FOR USE IN THE TREATMENT OF COVID-19 DISEASE AND PULMONARY FIBROSIS ASSOCIATED WITH COVID-19

Patent number:

No items found.

Disclosed are andrographolide derivatives for use as an antiviral agent in the treatment of COVID-19 disease or pulmonary fibrosis associated with COVID-19.

Countries:

Spain

Regions:

Valencian Community

Navarre

Centers:

CSIC, UNIVERSITAT DE VALENCIA, FUNDACION PARA LA INVESTIG MEDICA APLICADA, UNIVERSIDAD PUBLICA DE NAVARRA, UNIVERSITAT POLITECNICA DE VALENCIA, FUNDACION PARA LA INVESTIGACION MEDICA APLICADA, UNIVERSIDAD DE NAVARRA

Other entities:

Sectors:

Health

Subsectors:

TRL Level:

TRL 3 – experimental proof of concept

BRL Level:

PDF Link:

Download here

Video Link:

Watch it here

Sustainable Development Goal:

Applications

Comments

Other related patents

Health

LABORATORY ANIMAL HOUSING SYSTEM FOR THE STUDY OF THE TRANSMISSION OF INFECTIOUS AGENTS THROUGH DIRECT CONTACT (MACHINE-TRANSLATION BY GOOGLE TRANSLATE, NOT LEGALLY BINDING)

Countries

Spain

Health

FACIAL PROTECTION ELEMENT FOR PROTECTION AGAINST RISKS OF EXPOSURE TO INFECTIOUS BIOLOGICAL AGENTS

Countries

Spain

Health

SALTS OF PYRIDAZINO[2,3-A]PYRROLO[2,1-C]QUINOXALINE FOR THE TREATMENT OF LEISHMANIA INFECTIONS AND DISEASES THAT INVOLVE THE PROTEIN TYROSINE PHOSPHATASE 1B

Countries

Spain

Get back to patents directory